142 related articles for article (PubMed ID: 35545127)
1. Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients.
Cheung KS; Lam LK; Hui RWH; Mao X; Zhang RR; Chan KH; Hung IF; Seto WK; Yuen MF
Clin Mol Hepatol; 2022 Jul; 28(3):553-564. PubMed ID: 35545127
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
3. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants.
Zhang R; Liu D; Leung KY; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062734
[TBL] [Abstract][Full Text] [Related]
5. Effect of Moderate to Severe Hepatic Steatosis on Vaccine Immunogenicity against Wild-Type and Mutant Virus and COVID-19 Infection among BNT162b2 Recipients.
Cheung KS; Lam LK; Mao X; Tan JT; Ooi PH; Zhang R; Chan KH; Hung IFN; Seto WK; Yuen MF
Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992081
[TBL] [Abstract][Full Text] [Related]
6. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
Front Immunol; 2022; 13():918896. PubMed ID: 35757764
[TBL] [Abstract][Full Text] [Related]
8. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
9. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines.
Batıbay S; Ulucaköy RK; Günendi Z; Fidan I; Bozdayı G; Göğüş FN
Inflammopharmacology; 2022 Dec; 30(6):2089-2096. PubMed ID: 36282425
[TBL] [Abstract][Full Text] [Related]
11. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
Mok CKP; Cohen CA; Cheng SMS; Chen C; Kwok KO; Yiu K; Chan TO; Bull M; Ling KC; Dai Z; Ng SS; Lui GC; Wu C; Amarasinghe GK; Leung DW; Wong SYS; Valkenburg SA; Peiris M; Hui DS
Respirology; 2022 Apr; 27(4):301-310. PubMed ID: 34820940
[TBL] [Abstract][Full Text] [Related]
13. Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant.
Zhang R; Khong KW; Leung KY; Liu D; Fan Y; Lu L; Chan PC; Chen L; To KK; Chen H; Yuen KY; Chan KH; Hung IF
Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960189
[TBL] [Abstract][Full Text] [Related]
14. Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
Xiong X; Wong CKH; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng FWT; Lau KTK; Lee CH; Woo YC; Lui DTW; Wong ICK
Thyroid; 2022 May; 32(5):505-514. PubMed ID: 35216517
[No Abstract] [Full Text] [Related]
15. BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac.
Erol Ç; Kuloğlu ZE; Kayaaslan B; Esken G; Altunsoy A; Barlas T; Çınar G; Hasanoğlu İ; Oruç E; İncir S; Azap A; Korkmaz G; Turan Gökçe D; Kırımker OE; Coşkun Yenigün E; Ölçücüoğlu E; Ayvazoğlu Soy E; Çetinkünar S; Kurt Azap Ö; Can F; Haberal M
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515220
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents.
Rosa Duque JS; Wang X; Leung D; Cheng SMS; Cohen CA; Mu X; Hachim A; Zhang Y; Chan SM; Chaothai S; Kwan KKH; Chan KCK; Li JKC; Luk LLH; Tsang LCH; Wong WHS; Cheang CH; Hung TK; Lam JHY; Chua GT; Tso WWY; Ip P; Mori M; Kavian N; Leung WH; Valkenburg S; Peiris M; Tu W; Lau YL
Nat Commun; 2022 Jun; 13(1):3700. PubMed ID: 35764637
[TBL] [Abstract][Full Text] [Related]
17. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines.
Wong CKH; Mak LY; Au ICH; Lai FTT; Li X; Wan EYF; Chui CSL; Chan EWY; Cheng WY; Cheng FWT; Yuen MF; Wong ICK
J Hepatol; 2022 Nov; 77(5):1339-1348. PubMed ID: 35817224
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
Fonseca MHG; Pinto ACMD; Silva MFS; de Melo ACL; Vasconcelos GS; Dos Santos ER; de Carvalho Araújo FM; de Andrade LOM
Emerg Infect Dis; 2022 Jun; 28(6):1237-1240. PubMed ID: 35421324
[TBL] [Abstract][Full Text] [Related]
19. Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients.
Wong CKH; Lui DTW; Xiong X; Chui CSL; Lai FTT; Li X; Wan EYF; Cheung CL; Lee CH; Woo YC; Au ICH; Chung MSH; Cheng FWT; Tan KCB; Wong ICK
BMC Med; 2022 Oct; 20(1):339. PubMed ID: 36229814
[TBL] [Abstract][Full Text] [Related]
20. Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
Wong CKH; Xiong X; Lau KTK; Chui CSL; Lai FTT; Li X; Chan EWY; Wan EYF; Au ICH; Cowling BJ; Lee CK; Wong ICK
BMC Med; 2022 Mar; 20(1):119. PubMed ID: 35296305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
